Pulmonary hemodynamic effects and pulmonary arterial compliance during hypovolemic shock and reinfusion with human relaxin-2 (serelaxin) treatment in a sheep model

Article type: Research Article

Authors: Schiffner, René^{a; b; *} | Lehmann, Thomas^c | Bischoff, Sabine J.^d | Zippelius, Timo^a | Nistor, Marius^b | Schmidt, Martin^e

Affiliations: [a] Department of Orthopaedics, Jena University Hospital, Friedrich Schiller University, Jena, Germany | [b] Department of Neurology, Jena University Hospital, Friedrich Schiller University, Jena, Germany | [c] Institute of Medical Statistics, Computer Sciences and Documentation Science, Jena University Hospital, Friedrich Schiller University, Jena, Germany | [d] Central Animal Facility, Jena University Hospital, Friedrich Schiller University, Jena, Germany | [e] Institute for Biochemistry II, Jena University Hospital, Friedrich Schiller University, Jena, Germany

Correspondence: [*] Corresponding author: René Schiffner, MD, Department of Orthopaedic, Jena University Hospital - Friedrich Schiller University, Campus Eisenberg, Klosterlausnitzer Str. 81, D-07607 Eisenberg, Germany. Tel.: +49 36691 81292; Fax: +49 36691 81029; [email protected]

Abstract: BACKGROUND:Previous studies on the recombinant form of human relaxin-2 (serelaxin) have shown a decrease of pulmonary hemodynamics after serelaxin injection. Currently, the effect of serelaxin treatment during hypovolemia in a large animal model remains mostly unknown. METHODS:12 sheep were randomly assigned to a sham or serelaxin (30μg/kg serelaxin) group and underwent right heart catheterization. 50% of the estimated total blood volume were removed to induce hypovolemia, and subsequently retransfused 20 min later (reinfusion). Blood gases, heart rate, peripheral and pulmonary arterial oxygen saturation, systolic, diastolic and mean values of both pulmonary artery pressure (PAP) and pulmonary capillary wedge pressure (PCW) were measured. Cardiac output (CO), pulmonary vascular resistance (PVR), pulmonary arterial compliance (PAcompl) and systemic vascular resistance (SVR) were calculated. RESULTS:Hypovolemia and shock led to a similar decrease of PAP and PCW in both groups (p≤0.001). CO, SV and PAcompl decreased only in the control group (p≤0.05) and remained higher in the serelaxin-treated group. The results of this study suggest that serelaxin treatment did not negatively influence hemodynamic parameters during hypovolemic shock. CONCLUSION:The main conclusion of this study is that cardiopulmonary adaption mechanisms are not critically altered by serelaxin administration during severe hypovolemia and retransfusion.

Keywords: Pulmonary hemodynamics, relaxin-2, hypovolemia, reperfusion, reinfusion, shock, relaxin receptors, serelaxin, sheep model, right heart catheterisation

DOI: 10.3233/CH-180382

Journal: Clinical Hemorheology and Microcirculation, vol. 70, no. 3, pp. 311-325, 2018